Could a melanoma drug tame rare blood vessel disorders?
NCT ID NCT07549646
First seen Apr 25, 2026 · Last updated May 25, 2026 · Updated 3 times
Summary
This study tests whether trametinib, a drug already approved for melanoma, can help people with rare blood vessel growth problems caused by a specific genetic pathway. About 45 children and young adults (ages 2 months to 30 years) will take the drug for up to 3 years. The goal is to see if it shrinks abnormal vessels, improves symptoms, and enhances quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR ANOMALY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.